MiCheck® Test

  • MiCheck® has demonstrated the ability to differentiate aggressive from non-aggressive cancer and no cancer

  • MiCheck® demonstrates a compelling advantage in specificity over existing products, outperforming the benchmark PSA test as well as other tests such as % free PSA and the Prostate Health Index (PHI) in a head-to-head comparison

  • The other test’s lack of specificity has led to criticism due to the resulting unnecessary biopsies. The MiCheck® technology helps fill this substantial unmet clinical need by allowing a reduction in number of biopsies.

    • MiCheck® also offers:

    ✔ Ease of use – blood collection made at the same time as the blood draw for a PSA test
    ✔ No interruption to the clinician’s current workflow
    Clear clinical utility – single page well-defined report to help clinician determine whether patient needs biopsy or future follow-up in 6 to 12 months
    ✔ Timely delivery of results – ready for the next time the patient visits the clinician
    ✔ Dominant health economics in comparison to standard of care
    ✔ Early availability as LDT through a CLIA certified high complexity laboratory

    Achievements

    N

    2020

    MiCheck® Pancreatic Cancer Study Commenced

    N

    2019

    Laboratory Developed MiCheck® Prostate Cancer Test Roll-out

    N

    2018

    Completed MiCheck® Prostate Cancer Prospective Trial

    N

    2016

    Awarded Accelerating Commercialization Grant to Further Product Development

    N

    2014

    Clinical Validation Studies for MiCheck® Prostate Cancer Commenced

    N

    2011

    Received Venture Capital Funding for Commercialization

    N

    2009

    Showed Antibody Binding to Prostate Cancer Cells

    N

    2007

    Minomic Formed to Pursue Opportunity in Biomarkers Based on MIL-38 Monoclonal Antibody

    2015 Eureka Prize

    Excellence in Interdisciplinary Scientific Research

    Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.

    Learn More

    Find Out More Information

    • About our highly effective prostate cancer blood test >More
    • About how your company and Minomic could partner to deliver better prostate cancer diagnostics >More 

    13 + 12 =

    Address
    Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

    Phone
    International +612 9850 4000
    In Australia 02 9850 4000
    Compare your time zone with Sydney here

    Email
    info@minomic.com

    Finding Us
    We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

    Headquarters of Minomic

    Privacy Policy